Market
Novo Nordisk issues safety update or recall for Ozempic over vision loss by end of 2025?
2
Novo Nordisk•Ozempic•European Medicines Agency•EMA•Harvard University•Eli Lilly•Mounjaro•Britons•Wegovy
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Novo Nordisk or regulatory agencies
Story
Novo Nordisk's Ozempic Label Update Approved by EMA for Risk Reduction of Kidney Disease-Related Events Amid Vision Loss Study
Dec 13, 2024, 01:46 PM
Novo Nordisk's diabetes drug Ozempic has received a positive opinion from the European Medicines Agency (EMA) to update its label, which will now reflect the drug's potential to reduce the risk of kidney disease-related events. This approval follows a study that found a small number of patients experienced vision loss linked to Ozempic, corroborating previous research from Harvard University. Concurrently, Eli Lilly's Mounjaro is gaining popularity among Britons seeking obesity treatments, surpassing Novo Nordisk's Wegovy in preference. The recent findings suggest that while Ozempic may offer significant benefits for weight management and diabetes, its association with rare vision loss raises important safety considerations for patients and healthcare providers alike.
View original story
Similar markets
Stricter guidelines issued • 25%
Guidelines under review • 25%
Guidelines relaxed • 25%
No changes • 25%
Investigation ongoing • 25%
Causative link confirmed • 25%
No causative link found • 25%
Inconclusive results • 25%
Stable compared to 2024 • 25%
Increase from 2024 levels • 25%
Data not available • 25%
Decrease from 2024 levels • 25%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No publication • 25%
Product recall • 25%
No action taken • 25%
Safety label update • 25%
Other regulatory actions • 25%
